Recurrence-free survival after sentinel node biopsy in melanoma? [4]

British Journal of Dermatology

Volumn 155, Issue 3, 2006, Pages 631-632

  Hayes, A J ^a   Thomas, J M ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; DISEASE MARKER; DISSEMINATED CANCER; FALSE POSITIVE RESULT; LETTER; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE FREE SURVIVAL; SENTINEL LYMPH NODE BIOPSY;

DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MELANOMA; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 33747079509     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07373.x     Document Type: Letter

References (6)

1. Gutzmer R, Al Ghazal M, Geerlings H, Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 2005; 153:1137-41.
2. American Society of Clinical Oncology. Meetings and Education: Virtual Meeting. Interim Results of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in Clinical stage I Melanoma. (http://www.asco.org/ac/1,1003,_12- 002640-00_18-0034-00_19-0031917,00.asp) [accessed February 2006].
3. Morton DL, Thompson JF, Cochran AJ et al. Interim results of the Multicenter Selective Lymphadenectomy Trial (MSLT-1) in clinical stage 1 melanoma. J Clin Oncol 2005; 23 (Suppl.): S710. [Abstr.]
4. Thomspon JF, Uren RF, Shaw HM. Time for comprehensive reporting of MSLT-1. Authors' reply. Lancet Oncol 2006; 7:11-12.
5. Thomas JM. Time for comprehensive reporting of MSLT-1. Lancet Oncol 2006; 7:9-11.
6. Thomas JM. Caution with sentinel node biopsy in cutaneous melanoma. Br J Surg 2006; 93:129-30.